论文信息 - 1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial - 字舞流文

1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

C. Tournigand | C. Sautès-Fridman | S. Oudard | C. Chevreau | V. Verkarre | D. Maillet | M. Meylan | Y. Vano | R. Elaidi | M. Bennamoun | D. Borchiellini | E. Braychenko | D. Pannier | W. Fridman | M. Gross Goupil | P. Barthelemy | M. Moreira | C-M. Sun | A. Bougouin | L. Phan | P. Barthélémy